A Phase 3 interventional study of NBI-98854 in Tardive Dyskinesia, sponsored by Neurocrine Biosciences. Completed at 48 sites in 3 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2018-11-30.
Sponsored by Neurocrine Biosciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing valbenazine in Tardive Dyskinesia — 1 open to participants now, 1 under way, none of them phase 3. valbenazine · Tardive Dyskinesia.
Among the 14 studies testing valbenazine in Tardive Dyskinesia, this one is the 3rd largest by enrollment, is the only one that started in 2015, is one of 3 in phase 3, and was the 6th registered.
62 studies on the registry are indexed under Tardive Dyskinesia; 9 are open to participants now.
Browse Tardive Dyskinesia studies →1 of the 14 studies testing valbenazine in Tardive Dyskinesia is open now, in 1 country. Recruiting first, the newest first:
Neurocrine Biosciences · Sites in United States
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 7 Tardive Dyskinesia studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 4 · Phase 4 5
First in 2011; this study’s year is marked. 1 started in 2015.
This study's enrollment of 167 is above the median of 60 across 51 interventional studies indexed under Tardive Dyskinesia.
Median enrollment 101 across the 14 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 4 most frequent:
Neurocrine Biosciences is the lead sponsor of 87 studies on the registry; 17 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 23 (66%) have results posted.
13 studies in Tardive Dyskinesia by Neurocrine Biosciences: 2 open now, 2 under way, none of them phase 3. Of 10 finished, 9 (90%) have results posted.
Among the 13 studies in Tardive Dyskinesia by Neurocrine Biosciences, this one is the 2nd largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2015, is one of 3 in phase 3, and was the 6th registered.
Neurocrine Biosciences’s Tardive Dyskinesia studies by the year they started, since 2011.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing valbenazine in Tardive Dyskinesia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Neurocrine Biosciences’s 13 in Tardive Dyskinesia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Phase 3, open-label, study to evaluate the safety and tolerability of NBI-98854 administered once daily (qd) for a total of 48 weeks of treatment. This study will enroll approximately 150 medically stable male and female subjects with clinical diagnoses of schizophrenia or schizoaffective disorder with neuroleptic-induced TD or mood disorder with neuroleptic-induced TD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fixed dose of NBI-98854 administered once daily for 48 weeks
Drug: NBI-98854
Fixed dose of NBI-98854 administered once daily up to 48 weeks
Drug: NBI-98854
Number of Participants Monitored for Long-Term Safety of Valbenazine
Number of participants monitored for long-term safety through reporting of treatment-emergent adverse events and monitoring of vital signs, clinical laboratory values, and ECG. Summaries of all treatment-emergent AEs, treatment-related AEs, SAEs, and AEs leading to study drug discontinuation were prepared.
Time frame: 52 weeks
Severity of Tardive Dyskinesia (TD) Symptoms Assessed by Abnormal Involuntary Movements Scale (AIMS) Dyskinesia Total Score Change From Baseline at Week 48; On-site AIMS Raters
Severity of TD symptoms assessed by AIMS dyskinesia total score (sum of items 1 through 7), as assessed by On-Site AIMS video raters. The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.
Time frame: Baseline and Week 48
Severity of Tardive Dyskinesia (TD) Symptoms Assessed by Abnormal Involuntary Movements Scale (AIMS) Dyskinesia Total Score Change From Baseline; Central AIMS Video Raters
Severity of TD symptoms assessed by AIMS dyskinesia total score (sum of items 1 through 7), as assessed by the blinded, Central AIMS Video Raters. The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.
Time frame: Baseline, Change from Baseline at Week 8, and Change from Baseline at Week 52
Severity of Tardive Dyskinesia (TD) Symptoms Assessed by Abnormal Involuntary Movements Scale (AIMS) Dyskinesia Total Score Change From Baseline; On-Site AIMS Raters
Severity of TD symptoms assessed by AIMS dyskinesia total score (sum of items 1 through 7), as assessed by On-Site AIMS raters. The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.
Time frame: Baseline, Change from Baseline at Week 8, and Change from Baseline at Week 52
Clinical Global Impression - Global Improvement of Tardive Dyskinesia (CGI-TD) at Week 48
Clinician's perspective of the participant's overall improvement of TD symptoms since initiation of study drug dosing. The CGI-TD is based on a 7-point scale (range: 1=very much improved to 7=very much worse).
Time frame: Week 48
This study enrolled participants with clinical diagnoses of schizophrenia or schizoaffective disorder or mood disorder with neuroleptic-induced tardive dyskinesia (TD) from 45 centers in North America and Puerto Rico.
| Milestone | Valbenazine 40mg | Valbenazine 80mg | Valbenazine 80/40mg |
|---|---|---|---|
| Started | 49 | 107 | 11 |
| Completed | 20 | 74 | 9 |
| Not completed | 29 | 33 | 2 |
| Withdrew: Adverse event | 16 | 10 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Noncompliance | 1 | 6 | 2 |
| Withdrew: Withdrawal by subject | 4 | 8 | 0 |
| Withdrew: Death | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 5 | 6 | 0 |
| Withdrew: Physician decision | 2 | 2 | 0 |
Number of participants monitored for long-term safety through reporting of treatment-emergent adverse events and monitoring of vital signs, clinical laboratory values, and ECG. Summaries of all treatment-emergent AEs, treatment-related AEs, SAEs, and AEs leading to study drug discontinuation were prepared.
| Participants | Valbenazine 40mg | Valbenazine 80mg | Valbenazine 80/40mg |
|---|---|---|---|
| Number of Participants Monitored for Long-Term Safety of Valbenazine | 45 | 107 | 11 |
Severity of TD symptoms assessed by AIMS dyskinesia total score (sum of items 1 through 7), as assessed by On-Site AIMS video raters. The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.
| score on a scale | Valbenazine 40mg | Valbenazine 80mg | Valbenazine 80/40mg |
|---|---|---|---|
| Severity of Tardive Dyskinesia (TD) Symptoms Assessed by Abnormal Involuntary Movements Scale (AIMS) Dyskinesia Total Score Change From Baseline at Week 48; On-site AIMS Raters | -10.2 ± 1.2 | -11.0 ± 0.5 | -7.2 ± 2.2 |
Severity of TD symptoms assessed by AIMS dyskinesia total score (sum of items 1 through 7), as assessed by the blinded, Central AIMS Video Raters. The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.
| score on a scale | Valbenazine 40mg | Valbenazine 80mg | Valbenazine 80/40mg |
|---|---|---|---|
| At Baseline | 10.2 ± 0.6 | 10.0 ± 0.4 | 9.3 ± 0.8 |
| Change from Baseline at Week 8 | -4.5 ± 0.7 | -3.5 ± 0.4 | -4.9 ± 1.2 |
| Change from Baseline at Week 52 | -1.8 ± 1.0 | -3.3 ± 0.5 | 0.2 ± 1.3 |
Severity of TD symptoms assessed by AIMS dyskinesia total score (sum of items 1 through 7), as assessed by On-Site AIMS raters. The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.
| score on a scale | Valbenazine 40mg | Valbenazine 80mg | Valbenazine 80/40mg |
|---|---|---|---|
| At Baseline | 14.2 ± 0.8 | 15.0 ± 0.4 | 12.8 ± 1.4 |
| Change from Baseline at Week 8 | -7.1 ± 1.0 | -5.4 ± 0.5 | -7.4 ± 1.6 |
| Change from Baseline at Week 52 | -3.8 ± 1.2 | -4.6 ± 0.7 | -3.3 ± 1.8 |
Clinician's perspective of the participant's overall improvement of TD symptoms since initiation of study drug dosing. The CGI-TD is based on a 7-point scale (range: 1=very much improved to 7=very much worse).
| score on a scale | Valbenazine 40mg | Valbenazine 80mg | Valbenazine 80/40mg |
|---|---|---|---|
| Clinical Global Impression - Global Improvement of Tardive Dyskinesia (CGI-TD) at Week 48 | 1.7 ± 0.2 | 1.6 ± 0.1 | 2.3 ± 0.4 |
Collected over Up to 52 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Valbenazine 40 mg Through Week 4 | 0/163 (0%) | 0/163 (0%) | 0/163 (0%) |
| Valbenazine 40mg Week 4 Through Week 52 | 0/35 (0%) | 3/35 (8.6%) | 5/35 (14.3%) |
| Valbenazine 80mg Week 4 Through Week 52 | 1/107 (0.9%) | 17/107 (15.9%) | 15/107 (14%) |
| Valbenazine 80/40mg Week 4 Through Week 52 | 0/11 (0%) | 1/11 (9.1%) | 1/11 (9.1%) |
| Event | Valbenazine 40 mg Through Week 4 | Valbenazine 40mg Week 4 Through Week 52 | Valbenazine 80mg Week 4 Through Week 52 | Valbenazine 80/40mg Week 4 Through Week 52 |
|---|---|---|---|---|
| Joint dislocationInjury, poisoning and procedural complications | 0/163 | 0/35 | 0/107 | 1/11 |
| Lung cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/163 | 1/35 | 0/107 | 0/11 |
| Confusional statePsychiatric disorders | 0/163 | 1/35 | 0/107 | 0/11 |
| SchizophreniaPsychiatric disorders | 0/163 | 1/35 | 1/107 | 0/11 |
| Suicidal ideationPsychiatric disorders | 0/163 | 1/35 | 1/107 | 0/11 |
| DiverticulitisInfections and infestations | 0/163 | 0/35 | 2/107 | 0/11 |
| Abdominal painGastrointestinal disorders | 0/163 | 0/35 | 1/107 | 0/11 |
| Non-cardiac chest painGeneral disorders | 0/163 | 0/35 | 1/107 | 0/11 |
| CholelithiasisHepatobiliary disorders | 0/163 | 0/35 | 1/107 | 0/11 |
| OsteomyelitisInfections and infestations | 0/163 | 0/35 | 1/107 | 0/11 |
| Event | Valbenazine 40 mg Through Week 4 | Valbenazine 40mg Week 4 Through Week 52 | Valbenazine 80mg Week 4 Through Week 52 | Valbenazine 80/40mg Week 4 Through Week 52 |
|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 0/163 | 3/35 | 9/107 | 1/11 |
| HeadacheNervous system disorders | 0/163 | 2/35 | 6/107 | 0/11 |
Safety analysis set: included all participants who are enrolled into the study and received study drug, with the following two exclusions: (a) participants who withdrew from the study and returned all previously dispensed study drug with all doses present, and (b) participants who had no post-baseline data collected
| Age, Continuous(years) | Valbenazine 40mg | Valbenazine 80mg | Valbenazine 80/40mg | Total |
|---|---|---|---|---|
| Mean | 56.8 (30 to 80) | 57.8 (32 to 82) | 56.3 (42 to 69) | 57.4 (30 to 82) |
| Sex: Female, Male(Participants) | Valbenazine 40mg | Valbenazine 80mg | Valbenazine 80/40mg | Total |
|---|---|---|---|---|
| Female | 24 | 48 | 5 | 77 |
| Male | 21 | 59 | 6 | 86 |
| Ethnicity (NIH/OMB)(Participants) | Valbenazine 40mg | Valbenazine 80mg | Valbenazine 80/40mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 7 | 48 | 1 | 56 |
| Not Hispanic or Latino | 38 | 59 | 10 | 107 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Valbenazine 40mg | Valbenazine 80mg | Valbenazine 80/40mg | Total |
|---|---|---|---|---|
| Asian | 1 | 0 | 0 | 1 |
| Black or African American | 16 | 31 | 1 | 48 |
| Caucasian | 26 | 74 | 10 | 110 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 0 | 2 |
| Other: Latina | 1 | 0 | 0 | 1 |
| Other: Mulatto | 0 | 1 | 0 | 1 |
| BMI at Screening(kg/m^2) | Valbenazine 40mg | Valbenazine 80mg | Valbenazine 80/40mg | Total |
|---|---|---|---|---|
| Mean | 27.80 (18.0 to 40.8) | 28.95 (18.6 to 41.7) | 27.45 (22.2 to 33.3) | 28.53 (18.0 to 41.7) |
| Primary Psychiatric Diagnosis(Participants) | Valbenazine 40mg | Valbenazine 80mg | Valbenazine 80/40mg | Total |
|---|---|---|---|---|
| Schizophrenia/schizoaffective | 37 | 76 | 6 | 119 |
| Mood disorder | 8 | 31 | 5 | 44 |
| Age at Diagnosis(years) | Valbenazine 40mg | Valbenazine 80mg | Valbenazine 80/40mg | Total |
|---|---|---|---|---|
| Age at Schizophrenia/Schizoaffective Diagnosis | 30.9 (14 to 59) | 28.0 (9 to 63) | 26.2 (17 to 45) | 28.8 (9 to 63) |
| Age at Mood Disorder Diagnosis | 40.6 (32 to 50) | 36.9 (14 to 55) | 28.3 (11 to 62) | 36.8 (11 to 62) |
| Age at Tardive Dyskinesia Diagnosis(years) | Valbenazine 40mg | Valbenazine 80mg | Valbenazine 80/40mg | Total |
|---|---|---|---|---|
| Mean | 47.8 (24 to 73) | 49.2 (16 to 69) | 44.3 (20 to 66) | 48.4 (16 to 73) |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Mar 2015, a primary completion of Mar 2017 and a completion of Mar 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2018, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Valbenazine